Enzymatica rang in the company at Nasdaq First North
(Thomson Reuters ONE) -
Today at nine in the morning CEO Fredrik Lindberg rang the Nasdaq First North
Stock Market opening bell in Stockholm, to mark the first day of trading for
Enzymatica AB.
Enzymatica is a Swedish life science company whose business concept is to offer
effective aid against some of our most common diseases where viruses or bacteria
play a decisive role. Over a short period the company has developed a unique
oral spray for common colds and launched it on four markets, and in winter it
achieved the position as the most-sold article for common colds calculated in
kronor in Swedish pharmacies.
"We now have a unique product that keeps colds at bay and makes life easier for
many users. In two years we have moved from zero to number one in Swedish
pharmacies and thanks to the listing we have a stable foundation for our
continued work to establish ColdZyme internationally", says Fredrik Lindberg,
CEO of Enzymatica.
"The listing is part of creating a long-term platform for Enzymatica's continued
development. Through the listing the company gains a stamp of quality that is
important for a small company that does business with larger actors. We now have
the opportunity to position the company and create long-term contacts with the
stock market, which gives scope for greater institutional ownership," says
Lennart Nilsson, Chairman of the Board of Enzymatica.
ColdZyme has been on sale in Swedish pharmacies and health food stores since
autumn 2013 and in 2014 was also made available in Norway, Denmark and the
United Kingdom. With focus on building a strong Scandinavian domestic market
with its own sales organization, Enzymatica intends to expand ColdZyme to more
geographical markets through distribution agreements. A parallel objective of
the company in the long term is to commercialize more enzyme based products in
upper respiratory infections and oral health.
Net sales for 2014 were SEK 19.1 million, almost double the previous year. The
positive trend continued into the first part of 2015, when the company reported
continued strong sales growth. Sales in the first quarter of 2015 were SEK 7.0
million compared with SEK 2.5 million in the corresponding period of the
previous year.
For more information please refer to the company description drawn up for the
listing on Nasdaq First North. The document is available on the company's
website www.enzymatica.se/IR.
For further information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Phone: +46 708 86 53 70 | Email: fredrik.lindberg(at)enzymatica.com
Lennart Nilsson, Chairman of the Board, Enzymatica AB
Phone: +46 46 286 31 00. Email: ir(at)enzymatica.se
About Enzymatica AB
Enzymatica is a life science company whose business concept is to offer
effective aid against some of our most common diseases where viruses or bacteria
play a decisive role. Over a short period the company has developed a unique
oral spray for common colds, ColdZyme® and launched it on four markets. The
product became the leading article for common cold in Swedish pharmacies during
winter 2014-2015. The development program includes medical devices in upper
respiratory infections and oral health, and veterinary products. The company is
headquartered in Lund, Sweden. For more information, visit www.enzymatica.com.
Enzymatica's Certified Adviser is Erik Penser Bankaktiebolag.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Enzymatica AB via GlobeNewswire
[HUG#1928226]
Unternehmensinformation / Kurzprofil:
Datum: 15.06.2015 - 10:30 Uhr
Sprache: Deutsch
News-ID 400293
Anzahl Zeichen: 4262
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 134 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Enzymatica rang in the company at Nasdaq First North"
steht unter der journalistisch-redaktionellen Verantwortung von
Enzymatica AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
